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In 2014, the Los Angeles County Department of Public Health re-
ceived federal funding to improve the prevention and control of
hypertension in the population through team-based health care de-
livery models, such as pharmacist-led medication therapy manage-
ment.  To inform this work, the department conducted a 3-part
needs assessment consisting of 1) a targeted context scan of re-
gional policies and efforts, 2) a key stakeholder survey, and 3) a
public opinion internet-panel survey of Los Angeles residents.
Results suggest that political will and professional readiness ex-
ists  for  expansion  of  pharmacist-led  medication  management
strategies in Los Angeles. However, several infrastructure and
economic barriers, such as a lack of sufficient payment or reim-
bursement mechanisms for these services, impede progress. The
department is  using assessment results  to address barriers and
shape efforts in scaling up pharmacist-led programming in Los
Angeles.
Background
Approximately 75 million Americans aged 18 years or older have
hypertension, about half of whom have their hypertension under
control (1). The Healthy People 2020 goal is to increase the pro-
portion of adults with hypertension whose blood pressure is under
control to 61.2% by 2020 (2). As part of its comprehensive efforts
to improve hypertension management across the country, the Cen-
ters for Disease Control and Prevention (CDC) launched the 1422
State and Local Public Health Actions to Prevention Obesity, Dia-
betes, and Heart Disease and Stroke initiative (the 1422 initiative)
(3). The initiative comprises 15 strategies, 2 of which focus on the
use of team-based care models for hypertension prevention and
control: 1) increase engagement of nonphysician team members in
hypertension management, and 2) increase engagement of phar-
macists in providing medication therapy management (MTM) for
adults with high blood pressure. Pharmacist-led MTM is a distinct
service or group of services that optimize therapeutic outcomes for
individual patients (4). It is an example of a health care model
built on team-based care principles that are effective in chronic
disease management (5–7). Based on strong evidence that blood
pressure control improves when a pharmacist is included in team-
based care and the potential of MTM in supporting other chronic
disease conditions, the 1422 initiative incorporated strategies de-
signed to help scale up and spread these pharmacist-led interven-
tions and related team-based care approaches in the United States
(3,8).  In  2014,  the Los Angeles  County Department  of  Public
Health (DPH) became one of 4 large city jurisdictions funded by
CDC to administer the 1422 initiative.
To inform programs to address the strategies outlined above, DPH
conducted a 3-part community and stakeholder needs assessment,
focusing on ways to scale up MTM and comprehensive medica-
tion management (CMM) — an advanced, evidence-based patient-
centered MTM model — in both community and clinical settings.
This article presents findings from the assessment and describes
key needs and assets that can help steer efforts to improve hyper-
tension prevention and control in Los Angeles and other jurisdic-
tions.
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Community and Stakeholder Needs
Assessment
Guided by the ecological approach, DPH collected information at
the policy, organizational/community, and individual level (9).
The needs assessment was implemented in fall 2015. It comprised
1) a context scan of existing regional policies and efforts, 2) a key
stakeholder survey, and 3) a public opinion internet-panel survey
of Los Angeles residents.
Part I: Context scan of existing regional polices and
efforts
To understand the political and contextual landscape in which the
strategies of the 1422 initiative would be implemented, the DPH
team conducted a purposeful context scan of 1) state laws on li-
censed pharmacists’ scope of practice and 2) public health and
community-based programs aimed at promoting pharmacist-led
MTM/CMM. We identified policies, programs, and initiatives as a
result of conversations with subject matter experts.
State laws on licensed pharmacists’ scope of practice
Pharmacy practice in California made a critical shift in 2013 with
the passing of Senate Bill 493 (10). The bill declared pharmacists
to be “health care providers” who can bill for services, allowed
pharmacists to independently initiate and administer certain med-
ications and immunizations per state protocols, and authorized an
advanced practice pharmacist (APP) board recognition program.
Once fully established, the APP program will allow certified APPs
to perform patient assessments, refer patients to other health care
providers, and coordinate with patients’ physicians to participate
in the evaluation and management of disease. At present, phar-
macists in California are allowed to perform many of these tasks
under  collaborative practice  agreements  made with individual
physicians and health care providers (11). However, the APP pro-
gram will give them these rights without requiring collaborative
practice agreements, ultimately allowing pharmacists greater flex-
ibility in providing MTM/CMM services. Although Senate Bill
493 is an important step forward for the pharmacist community,
the infrastructure and mechanisms needed to carry out such pro-
grams are mostly undeveloped; for example, efforts to develop
and adopt the protocols needed to enact Senate Bill 493 continue
nearly 3 years after the bill was signed into law (12).
Public health and community-based programs
Many agencies in California have begun to test or scale up MTM/
CMM approaches. The California Department of Public Health re-
leased a report in 2015 describing some of these efforts (13). The
report discussed the unique education, training, and credentialing
needs of pharmacists and offered evidence of the favorable impact
of CMM on patient outcomes. The report highlighted several pilot
projects, including a project in the Los Angeles area that provided
CMM services to high-risk patients in one of the country’s largest
federally qualified health centers.
Other community-based efforts targeting low-income neighbor-
hoods  in  Los  Angeles  have  incorporated  similar  MTM/CMM
strategies, including the LA Barbershop project in which African
American men (aged 35–79 y) were screened and referred for hy-
pertension management during their usual barbershop visits (R.
Victor, A. Reid, R. Elashoff,  unpublished data, 2015). Finally,
MTM/CMM approaches have been promoted by nonprofit organ-
izations such as the American Heart Association, which recently
established the Western States Affiliate Blood Pressure Task Force
to help states improve management of high blood pressure in vul-
nerable populations. One of the principal goals of the task force is
to study the potential impact of MTM/CMM on health care and
medical practices in health systems in in California (14).
Part II: Key stakeholder survey
In October 2015, DPH collaborated with the University of South-
ern California School of Pharmacy and its partners to host the first
annual pharmacist leadership symposium on opportunities to align
advanced community pharmacy practice with unmet healthcare
needs. The event brought together representatives from retail chain
pharmacies, independent community pharmacies, academia, pro-
fessional organizations, nonprofit organizations, insurance com-
panies and other payers, and local health departments. Presenta-
tions and discussions at the symposium centered on opportunities
for pharmacists to meet the chronic disease needs of communities
and strategies to effectively scale up advanced pharmacy practices
such as MTM/CMM in Los Angeles.
After the symposium, all 56 attendees were asked to complete a
17-item paper questionnaire developed by DPH staff; the items
were informed by a literature review. The questionnaire included
both closed- and open-ended questions and took approximately 10
minutes to complete (Box 1). Questions captured data on parti-
cipant perspectives on priority actions needed to scale up phar-
macist-led patient care activities, organizational readiness for im-
plementing such systems or models of practice, and barriers to de-
livering MTM/CMM services. Collected data were managed and
tallied by using Microsoft Excel software (Microsoft Corporation).
This  program improvement project  was considered an exempt
activity  by  the  Los  Angeles  County  DPH institutional  review
board.
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Box 1. Selected Questions From Key Stakeholder Survey, Administered to
Attendees of the Symposium on Opportunities to Align Advanced
Community Pharmacy Practice with Unmet Healthcare Needs, University of
Southern California, October 2015
Q7. Of these options, which do you consider to be the 3 most important ac-
tions to consider regarding pharmacists’ patient care services in Califor-
nia?
• Increase health care provider awareness of and receptivity to phar-
macists’ patient care services
• Increase patient awareness of and receptivity to pharmacists’ patient
care services
• Improve reimbursement procedures or options among private insurers
for pharmacists’ patient care services
• Advance federal policy at Centers for Medicare & Medicaid Services to
expand coverage of pharmacists’ patient care services
• Build support among health care institutions by highlighting the busi-
ness case for pharmacists’ patient care services
• Standardize and increase access to training of pharmacists for ad-
vanced patient care practices
• Scale the use of collaborative practice agreements to expand phar-
macists’ patient care services in the community
Q11. Please indicate the extent to which your organization has implemen-
ted the following systems or practices: [Response options: fully in place,
partially in place, under development, not in place, don’t know].
Q12. If not already in place, how feasible would it be to implement or scale
these systems or practices within your organization? [Response options:
very feasible, somewhat feasible, somewhat not feasible, not at all feas-
ible]
Q13. Even if not currently in place, how important are each of these sys-
tems or practices to improve patient outcomes related to medication and
chronic disease management? [Response options: very important, some-
what important, somewhat not important, not important at all]
Q14. What, if any, barriers or challenges exist to implementing or scaling
any of the above practices within your organization? Please explain.
[Systems or practices referenced in questions 11–14]
• Mechanisms to perform or obtain necessary assessments of a patient’s
health status (eg, in-person assessments in private or semi-private set-
tings)
• Comprehensive medication therapy reviews (MTRs) to identify, resolve,
and prevent medication-related problems, including adverse drug events
• Systems to provide patients with personal medication records (PMRs)
that catalog prescription and nonprescription medications, herbal
products, and other dietary supplements to assist in medication therapy
self-management
• Verbal education and training designed to enhance patient understand-
ing and track progress of self-management
• Mechanisms to provide information, support services, and other re-
sources designed to enhance patient adherence to therapeutic regimens
• Systems to monitor and evaluate the patient’s response to therapy, in-
cluding safety and effectiveness
• Consulting services and interventions to address medication-related
problems, including referral to a physician or other health care profession-
al when necessary
• Systems to document care delivered and communicate essential inform-
ation to the patient’s other primary care providers
• Coordination and integration of MTM [medication therapy management]
services within the broader health care management services being
provided to the patient
Of 56 attendees, 26 (46%) completed the survey; not all respond-
ents answered all questions. Thirteen survey respondents reported
their level of experience as at least 11 years or more, and 11 re-
spondents self-identified as a pharmacist or as a member of phar-
macy leadership in California. Respondents rated the following as
top priority actions for scaling up pharmacist-led patient care ser-
vices: 1) improve reimbursement procedures or options among
private insurers, 2) advance federal policy at the Centers for Medi-
care & Medicaid Services to expand coverage of pharmacists’ ser-
vices, and 3) increase health care provider awareness of and re-
ceptivity to pharmacists’ services. Professional practices and pa-
tient  care  system elements  (eg,  systems to  communicate  with
primary care providers, patient education to support self-manage-
ment, mechanisms to obtain patient health information) were con-
sistently rated as important (Table 1). However, participants were
not as optimistic about the current level of implementation in prac-
tice or the feasibility of implementing these models of practice.
Respondents identified many barriers associated with the scale-up
and spread of pharmacist-led patient care services: 7 respondents
indicated reimbursement and funding challenges; 6 respondents
indicated health care provider challenges (ie, need for increased
physician/provider awareness, support, and coordination); and 5
respondents indicated limited electronic record capabilities (eg,
need for electronic medical record systems that readily allow for
pharmacist–provider communications).
Part III: Public opinion internet-panel survey
Survey methods
In December 2015, DPH commissioned Global Strategy Group to
conduct a clinical services internet-panel survey of adult residents
of Los Angeles. DPH developed the survey questions with sup-
port from Global Strategy Group, drawing from nationally valid-
ated surveys and internally developed instruments. Data were col-
lected during 2 weeks and included data on demographics, health
behaviors  and attitudes,  opinions of  health care providers  (eg,
pharmacists), and personal health status. The survey was admin-
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istered in English and Spanish to adults (aged ≥18 y) who resided
in Los Angeles. Participants were recruited from existing parti-
cipant panels established by reputable panel providers via email,
social media, and mobile telephone applications. Incentives were
provided after survey completion based on a structured incentive
schedule established by the panel provider; rewards were determ-
ined based on the length of the survey and could be redeemed for
miles, gift cards, or other items. All collected data were weighted
to account for differential sampling rates, differential nonresponse,
and other variables (marital status, education, income, and other
demographic  distributions  of  Los  Angeles  County).  Data  for
demographic weights were based on the 2013 American Com-
munity Survey (15) and the 2011 Los Angeles County Health Sur-
vey (16).
For  the  pharmacist-led  MTM component  of  the  survey,  parti-
cipants were asked 2 questions and provided with the following
definition of pharmacist-led MTM: “Medication therapy manage-
ment (MTM) is a medical service provided to patients by phar-
macists to optimize drug and improve therapeutic outcomes. MTM
includes a broad range of professional activities, including but not
limited to performing patient assessment and/or a comprehensive
medication review, formulating a medication treatment plan, mon-
itoring efficacy and safety of medication therapy, enhancing med-
ication adherence through patient empowerment and education,
and  documenting  and  communicating  MTM  services  to  pre-
scribers in order to maintain comprehensive patient care.” The 2
questions were 1) “To your knowledge, do you have access to
MTM [medication therapy management] at the place where you
usually go or last went for health care?” and 2) “If MTM were
available where you currently go for health care, how interested
would you be in receiving this  service when you need to take
medicine? If  you have used MTM please check that  box.” All
study materials were reviewed and approved by the DPH institu-
tional review board before field implementation.
Data analysis and survey results
We generated descriptive statistics to describe participant demo-
graphics and understand the response profiles of those who were
aware of having access to MTM services and would be interested
in receiving MTM services. To further explore participant interest
in receiving MTM services (dependent variable), we performed
binary logistic regression. Model covariates, which were entered at
the same time in the final model, included demographic character-
istics (ie, age, sex, race/ethnicity, education, relationship status, in-
surance status), health indicators (ie, number of chronic condi-
tions ever diagnosed, self-reported health status), knowledge of
having access to MTM, and level of comfort discussing health is-
sues with pharmacists. All data analyses were conducted by using
StataSE version 14.0 (StataCorp LP).
Of 33,766 people initially invited to participate in the internet-pan-
el survey, 1,751 clicked on the survey link. Among those who
clicked on the link, 737 people were excluded because 1) they did
not meet survey criteria or quotas established by Global Strategy
Group to ensure accurate representation of the Los Angeles popu-
lation (n = 460), 2) they did not complete the survey (n = 175), or
3) they were invalidated because of speeding (when respondents
answer questions so quickly that they probably are not thought-
fully answering the questions) or straight lining (when respond-
ents choose the same response for every question and are prob-
ably not thoughtfully answering the questions) (n = 102). Our ana-
lytic sample consisted of 1,014 participants. Approximately  10%
of the data were missing; only those with complete data (n = 968)
were included in the model analysis.
Most  participants  were aged 25 to 64 (71.2%),  were Hispanic
(42.8%) or white (30.4%), and reported being in excellent or very
good health (55.9%) (Table 2). Approximately one-third (34.8%)
reported having at least 2 chronic conditions. Approximately 9%
reported having access to MTM services where they usually go for
care, and 41.3% expressed interest in using or having used MTM
services, regardless of what was currently available. Among parti-
cipants who expressed interest in using MTM, 51.2% were wo-
men, 54.0% reported excellent to very good health, and 85.5%
said they were generally comfortable speaking to a pharmacist.
The binary logistic model indicated that older age (≥65 y) pre-
dicted interest in MTM (P = .02). The model also indicated that
those who were aware of having access to MTM services were
less likely than those who had no knowledge to express interest in
receiving MTM services (P < .001). Additionally, compared with
those  who felt  comfortable  talking  to  pharmacists  about  their
health, those who were not comfortable speaking with their phar-
macists were more likely to be interested in receiving MTM ser-
vices (P < .001). Although somewhat unexpected, these results
align with research on the challenges of developing client interest
in MTM services and the complexities of patient decision making
(17,18). Factors that inform patients’ decision making are com-
plex, and the process is often influenced not only by the perceived
value of an intervention but also by the level of perceived harm
from their condition (19,20). Although more research is needed on
patients’ level of comfort in talking to pharmacists, patients who
are not comfortable talking to an individual pharmacist may per-
ceive the team-oriented MTM as a desirable alternative.
Discussion
Our needs assessment suggests challenges and opportunities for
scaling up pharmacist-led MTM/CMM interventions. First, legis-
lation (ie, Senate Bill 493) supports advancing MTM/CMM prac-
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tice. However, infrastructure for expanding the practice is lacking.
Second, many in the pharmacist community are ready to take ac-
tion to scale up and spread MTM/CMM, but the lack of mechan-
isms for reimbursement of more advanced pharmacist practices is
a key barrier to expansion. Third, although many people report
feeling comfortable discussing health issues with their pharmacist,
this comfort level does not necessarily translate into interest in
MTM services. Our assessment also led to the creation of a syn-
thesized list of needs and assets (Box 2). This information could
be useful for informing the scale-up and spread of MTM/CMM
programming in Los Angeles and elsewhere in the United States.
Box 2. Synthesis of Needs and Assets Associated With the Scale-Up and
Spread of Medication Therapy Management and Comprehensive
Medication Management Programming in Los Angelesa
Needs
Interoperable electronic medical record systems that facilitate pharmacist
and provider communication (ie, capability to share information across dif-
ferent software platforms).
Clinic workflows that facilitate integration of pharmacists into primary care
settings.
Payment and reimbursement reform for pharmacists, particularly in the
community setting.
Increased health care provider awareness of and receptivity to phar-
macists’ patient care services (eg, calm fears among health care pro-
viders of losing patients to other providers).
Increased leadership or champions at all levels of practice advocating for
integration of pharmacists within team-based care models.
Increased patient awareness and receptivity to the broadened scope of
work of pharmacists in the health care team.
Assets
Pharmacists represent a highly skilled workforce that is currently underutil-
ized and is ready and willing to expand their contributions to the health
care team.
Federal and state support for integrating pharmacists into health care
teams (ie, Patient Protection and Affordable Care Act, Senate Bill 493 in
California).
Emerging evidence of the positive impact of increasing the role of phar-
macists on the health care team and resultant best practices from pilot
projects in diverse populations.
Overall public familiarity with pharmacists and comfort working with them.
With a growing demand for primary care services, there is increased oppor-
tunity to demonstrate the potential value in incorporating pharmacists
more broadly into team care models.
Designation of pharmacists as health care providers in California, allowing
for increased opportunities to establish reimbursement mechanisms for
an expanded scope of work.
a Data sources: Butler et al (13), Los Angeles County Department of Public
Health.
Although  this  community  and  stakeholder  needs  assessment
provides insights into readiness to scale up MTM/CMM strategies
in Los Angeles, it has limitations. First, the context scan of MTM/
CMM efforts in Los Angeles and across California was not ex-
haustive; it was purposefully focused on legislative and program-
matic strategies. Second, results from the leadership symposium
survey offered only a snapshot of pharmacist and public health
leadership opinions and did not capture data on the viewpoints of
other  health care professionals  (eg,  physicians,  nurses).  Other
viewpoints may be important, because key processes in the health
care  system are  not  under  the  purview of  pharmacy or  public
health communities. Third, the sample size was small and repres-
ented a group of providers who self-selected to attend a meeting
promoting the use of MTM/CMM, potentially biasing the results
of the survey. Finally, the internet-panel survey posed challenges
to precise interpretation of public support for MTM services. Sur-
vey limitations include the following: 1) the recruitment mechan-
ism used by internet-panel surveys lends itself to a high nonre-
sponse rate, which could have limited the survey’s validity; 2) al-
though most Los Angeles residents speak mostly English or Span-
ish at home, participant views may differ and not reflect the views
of other populations; 3) because the survey was internet based,
people who have a limited understanding of MTM/CMM pro-
gramming and its definition may have been underrepresented; 4)
questions assessing interest in MTM did not provide qualifying in-
formation such as cost or scope of MTM; and 5) the quantitative
nature of the survey did not allow for exploration of participant
reasoning for their interest or lack thereof.
Public health and other health professions can capitalize on the op-
portunities identified in our needs assessment to better coordinate
care for hypertension management in the community.  Lessons
learned from the effort in Los Angeles can inform other jurisdic-
tions interested in strengthening its infrastructure for MTM/CMM
programs.
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Tables
Table 1. Responses to a Questionnaire on Implementation of Current Pharmacy Practices, Feasibility of Implementing Future Actions, and Perceived Importance to
Patient Outcomes, Pharmacy Leadership Symposium, Los Angeles County, 2015a
Pharmacy Practice





Answered “Very” or “Somewhat” Important
in Improving Patient Outcomes (%)
Mechanisms to perform or obtain
assessments of patient's health status (eg,
in-person assessments in private or semi-
private settings)
10 of 21 (47.6) 12 of 15 (80.0) 19 of 19 (100.0)
Comprehensive medication therapy
reviews to identify, resolve, and prevent
medication-related problems, including
adverse drug events
13 of 21 (61.9) 13 of 16 (81.3) 19 of 19 (100.0)
Systems to provide patients with personal
medication records that catalog
prescription and nonprescription
medications, herbal products, and other
dietary supplements to assist in
medication therapy self-management
11 of 21 (52.4) 13 of 16 (81.3) 19 of 19 (100.0)
Verbal education and training designed to
enhance patient understanding and track
progress in self-management
10 of 20 (50.0) 15 of 17 (88.2) 19 of 19 (100.0)
Mechanisms to provide information,
support services, and other resources
designed to enhance patient adherence to
therapeutic regimens
11 of 21 (52.4) 14 of 16 (87.5) 19 of 19 (100.0)
Systems to monitor and evaluate the
patient’s response to therapy, including
safety and effectiveness
11 of 20 (55.0) 16 of 16 (100.0) 19 of 19 (100.0)
Consulting services and interventions to
address medication-related problems,
including referral to a physician or other
health care professional when necessary
13 of 21 (61.9) 13 of 15 (86.7) 19 of 19 (100.0)
Systems to document care delivered and
communicate essential information to the
patient’s primary care providers
12 of 21 (57.1) 12 of 15 (80.0) 19 of 19 (100.0)
Coordination and integration of medication
therapy management services within the
broader health care management services
being provided to the patient
12 of 21 (57.1) 14 of 16 (87.5) 19 of 19 (100.0)
a Twenty-six of 56 symposium attendees completed the 17-item survey. Not all respondents answered all questions; denominators indicate the number of parti-
cipants who answered the question.
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Table 2. Participant Demographics, Access to MTM, and Interest in Receiving MTM Services: Results of a Los Angeles County Internet-Panel Survey, 2015

















Not married, but living with partner 91 (7.2)
Single 359 (35.3)
Divorced/separated/widowed 128 (11.0)
Prefer not to say 7 (0.6)
Insurance status





Other/don’t know 79 (9.6)
Education
High school diploma or less 183 (30.5)
Some college or technical school 227 (25.1)
Associate’s degree 75 (8.5)
Bachelor’s degree 324 (21.9)
Abbreviation: MTM, medication therapy management.
a All collected data were weighted to account for differential sampling rates, differential nonresponse, and other variables (marital status, education, income, and
other demographic distributions of Los Angeles County). Data for demographic weights were based on the 2013 American Community Survey (15) and the 2011
Los Angeles County Health Survey (16).
b Survey participants were provided with the following definition of pharmacist-led MTM: “Medication therapy management (MTM) is a medical service provided to
patients by pharmacists to optimize drug and improve therapeutic outcomes. MTM includes a broad range of professional activities, including but not limited to per-
forming patient assessment and/or a comprehensive medication review, formulating a medication treatment plan, monitoring efficacy and safety of medication
therapy, enhancing medication adherence through patient empowerment and education, and documenting and communicating MTM services to prescribers to
maintain comprehensive patient care.”
(continued on next page)
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(continued)
Table 2. Participant Demographics, Access to MTM, and Interest in Receiving MTM Services: Results of a Los Angeles County Internet-Panel Survey, 2015
Characteristics No. (Weighted Proportiona) (n = 1,014)
Graduate degree 198 (13.3)
Prefer not to answer 7 (0.7)
Self-reported health status
Excellent/very good 587 (55.9)
Good/fair 413 (42.4)
Poor 14 (1.6)
No. of chronic conditions ever diagnosed
0 or 1 649 (65.2)
2 or 3 247 (23.0)
≥4 118 (11.8)
Comfort speaking to pharmacist
Extremely comfortable 119 (13.6)
Very comfortable 259 (24.2)
Somewhat comfortable 404 (38.6)
Not very comfortable 146 (14.6)
Not at all comfortable 86 (9.1)
Do you have access to MTM at the place where you usually go or last went for care?b
Yes 76 (9.1)
No 267 (25.3)
Don’t know/not sure 671 (65.6)
If MTM were available, how interested in receiving the service when you need to take medication?b
Very interested 77 (8.1)
Somewhat interested 317 (31.0)
Not very interested 308 (28.5)
Not interested at all 292 (30.2)
Have used MTM 20 (2.2)
Abbreviation: MTM, medication therapy management.
a All collected data were weighted to account for differential sampling rates, differential nonresponse, and other variables (marital status, education, income, and
other demographic distributions of Los Angeles County). Data for demographic weights were based on the 2013 American Community Survey (15) and the 2011
Los Angeles County Health Survey (16).
b Survey participants were provided with the following definition of pharmacist-led MTM: “Medication therapy management (MTM) is a medical service provided to
patients by pharmacists to optimize drug and improve therapeutic outcomes. MTM includes a broad range of professional activities, including but not limited to per-
forming patient assessment and/or a comprehensive medication review, formulating a medication treatment plan, monitoring efficacy and safety of medication
therapy, enhancing medication adherence through patient empowerment and education, and documenting and communicating MTM services to prescribers to
maintain comprehensive patient care.”
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